The chief executive of diagnostics firm Biotrin plans to launch a new company just nine months after he completed a €15 million buyout of Biotrin.
Cormac Kilty is looking at ways to fund a spin-out from Biotrin. It would be based on the company’s biomarkers technology, which can assess organ and tissue damage.
Biotrin has just launched a new product, which it claims can detect acute kidney injuries much earlier than existing tests.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team